Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares were down 19.4% on Thursday . The stock traded as low as $7.50 and last traded at $7.70. Approximately 225,305 shares traded hands during trading, a decline of 20% from the average daily volume of 280,484 shares. The stock had previously closed at $9.55.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the company. Leerink Partnrs raised Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. Leerink Partners started coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They set an "outperform" rating and a $28.00 price objective for the company. Guggenheim reaffirmed a "buy" rating and issued a $19.00 target price on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an "overweight" rating and a $30.00 price objective for the company. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $25.67.
View Our Latest Stock Report on Maze Therapeutics
Maze Therapeutics Trading Up 5.2 %
The stock has a 50 day moving average of $10.13.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported ($18.32) EPS for the quarter, missing the consensus estimate of ($7.60) by ($10.72).
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new position in Maze Therapeutics in the first quarter worth about $190,000. Bessemer Group Inc. acquired a new stake in shares of Maze Therapeutics in the 1st quarter worth about $5,305,000. Finally, General Catalyst Group Management LLC acquired a new stake in shares of Maze Therapeutics in the first quarter valued at approximately $11,405,000.
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
See Also
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
